MIRA MIRA PHARMACEUTICALS INC revenue, earnings and financials
For the quarter ended June 30, 2026, MIRA PHARMACEUTICALS INC reported revenue of n/a, net income of −$1.21M and diluted EPS of −$0.03; for the fiscal year ended December 2025 revenue was n/a.
MIRA annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income n/a, net income −$10.4M (margin n/a), EPS −$1.35
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income n/a, net income −$7.85M (margin n/a), EPS −$0.51
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income n/a, net income −$12.0M (margin n/a), EPS −$0.85
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income n/a, net income −$7.06M (margin n/a), EPS −$0.40
MIRA quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$1.21M, EPS −$0.03
- Quarter ended Mar 31, 2026: revenue n/a, net income −$1.15M, EPS −$0.03
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$5.98M, EPS $0.03
- Quarter ended Sep 30, 2025: revenue n/a, net income −$1.14M, EPS −$1.18
- Quarter ended Jun 30, 2025: revenue n/a, net income −$1.54M, EPS −$0.09
- Quarter ended Mar 31, 2025: revenue n/a, net income −$1.78M, EPS −$0.11
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$2.40M, EPS −$0.11
- Quarter ended Sep 30, 2024: revenue n/a, net income −$2.04M, EPS −$0.14
- Quarter ended Jun 30, 2024: revenue n/a, net income −$1.69M, EPS −$0.11
- Quarter ended Mar 31, 2024: revenue n/a, net income −$1.72M, EPS −$0.15
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$5.79M, EPS −$0.39
- Quarter ended Sep 30, 2023: revenue n/a, net income −$3.59M, EPS −$0.26
- Quarter ended Jun 30, 2023: revenue n/a, net income −$1.27M, EPS −$0.10
- Quarter ended Mar 31, 2023: revenue n/a, net income −$1.34M, EPS −$0.10
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$1.35M, EPS n/a
- Quarter ended Sep 30, 2022: revenue n/a, net income −$1.81M, EPS −$0.14
- Quarter ended Jun 30, 2022: revenue n/a, net income −$2.42M, EPS −$0.19
- Quarter ended Mar 31, 2022: revenue n/a, net income −$1.48M, EPS n/a
MIRA cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$4.66M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$5.56M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$4.53M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$5.60M, share buybacks n/a
MIRA balance sheet
- Jun 30, 2026: cash $3.61M, total assets $8.20M, total liabilities $40.8K, shareholders' equity $8.16M
- Mar 31, 2026: cash $4.82M, total assets $9.46M, total liabilities $115K, shareholders' equity $9.35M
- Dec 31, 2025: cash $6.35M, total assets $11.1M, total liabilities $702K, shareholders' equity $10.4M
- Sep 30, 2025: cash $2.64M, total assets $7.63M, total liabilities $83.9K, shareholders' equity $7.55M
- Jun 30, 2025: cash $730K, total assets $868K, total liabilities $298K, shareholders' equity $570K
- Mar 31, 2025: cash $1.21M, total assets $1.40M, total liabilities $106K, shareholders' equity $1.29M
- Dec 31, 2024: cash $2.83M, total assets $2.92M, total liabilities $723K, shareholders' equity $2.20M
- Sep 30, 2024: cash n/a, total assets $4.27M, total liabilities $693K, shareholders' equity $3.57M
Is MIRA profitable?
No. MIRA PHARMACEUTICALS INC lost $9.48M over the last four quarters.
What is MIRA's EPS?
Diluted earnings per share over the last four quarters were −$1.21; −$0.03 in the latest quarter.